Document is current
Any future updates will be listed below
-
Authors
Hinchliffe, Chloe
Rehman, Rana Zia Ur
Pinaud, Clemence
Branco, Diogo
Jackson, Dan
Ahmaniemi, Teemu
Guerreiro, Tiago
Chatterjee, Meenakshi
Manyakov, Nikolay V.
Pandis, Ioannis
Davies, Kristen
Macrae, Victoria
Aufenberg, Svenja
Paulides, Emma
Hildesheim, Hanna
Kudelka, Jennifer
Emmert, Kirsten
Van Gassen, Geert
Rochester, Lynn
van der Woude, C. Janneke
Reilmann, Ralf
Maetzler, Walter
Ng, Wan-Fai
Del Din, Silvia
,
-
Funding
Funding for this research was provided by:
EU Innovative Medicines Initiative 2 Joint Undertaking (853981)
National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre
NIHR/Wellcome Trust Clinical Research Facility
- License Information
-
More Information
Article History
Received: 25 September 2023
Accepted: 21 May 2024
First Online: 5 June 2024
Declarations
:
: This feasibility study has been registered at the German Clinical Trial Registry (DRKS00021693) and was approved by the ethics committee of the Medical Faculty of Kiel University (D 491/20) and the HRA and Health and Care Research Wales (HCRW) (IRAS project ID 282329, REC reference 20/PR/0185). Patient interviews are pseudonymous for storage and only accessible by data analysts within the consortium. Ethical approval for the clinician (anonymised) interviews reported in this paper (which was outside the scope of the FS protocol) was granted by Newcastle University (7421/2020). Verbal consent was taken as interviews were primarily held over video conferencing software or telephone.
: Not applicable.
: S. Del Din reports consultancy activity with Hoffmann-La Roche Ltd. outside of this study. N. V. Manyakov, R. Z. U. Rehman and M. Chatterjee employees of Janssen Research & Development and may hold company stocks/stock options.
